COPD Flashcards

1
Q

Short-acting Beta Agonist

Common indications

A
  1. COPD- releive breathlessness brought on by exercise
  2. Asthma- used in conjunction with other agents
  3. Hyperkalaemia- nebulised salbutamol may be used in conjunction with other treatments for the urgent treatment of hyperkalaemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

B2-agonist MOA

A
  • B2-receptors are found on the smooth muscle of the bronchi, GIT, uterus and blood vessels
  • Stimulation of the GPCR activates a signalling cascade that leads to the relaxation of smooth muscle
  • Improves airflow reduce SOB
  • B2-agonist stimulates Na/K/ATPase pumps on the cell surface
    • Shifting K into the cell- useful for hyperkalaemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

B2-Agonist important side effects

A
  • Tachycardia
  • Palpitations
  • Anxiety
  • Tremor
  • Increase serum glucose levels- diabetes
  • Muscle cramps
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

B2-agonist

Warnings

A
  • Only use LABA in asthma if there is an ICS treatment used as well
  • Without the steroid there is an increase mortality rate
  • Care should be given to people with CVD
    • Tachycardia= worsen angina, provoke arrhythmias
    • Especially important when using as part of the hyperkalaemia treatment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

B2-agonist important interactions

A
  • Beta blockers- may reduce the effectiveness of the agonist
  • Extensive use of B2 with ICS and theophylline may lead to hypokalaemia monitor U&E
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

B2- agonist

Monitoring + advise

A
  • Symptom severity
  • Peak flow meter
  • Spirometry
  • Exacerbations
  • Tell patients this will help there breathing (symptoms) but not treat/cure the disease.
  • If they need to use B2-agonist regularly then they need to get there other inhalers stepped up
  • Make sure they clean their inhaler regularly
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

ICS

Common indications

A
  • Asthma- treat airway inflammation and control symptoms at step 2 of asthma therapy when SABA fails
  • COPD- to control symptoms and prevent exacerbations in patients who have severe airflow obstruction on spirometry and or recurrent exacerbations
    • Can be used in combination with LABA + LAMA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

ICS

Mechanism of action

A
  • Corticosteroids pass through the plasma membrane and interact with receptors in the cytoplasm
  • The activated receptor then passes into the nucleus to modify transcription of a large number of genes
    • Pro-inflammatory cytokines, interleukins and chemokines are downregulated
    • While anti-inflammatory proteins are upregulated
  • In the airways this reduces mucosal inflammation, widens the airways and reduces mucus secretion
  • Improves symptoms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

ICS

Important adverse events

A
  • Immunosupressive effect in the mouth increases risk of oral thrush
  • Hoarse voice
  • In COPD, they can increase the risk of pneumonia
  • Very little is absorbed into the blood, so there are few systematic adverse effect unless very high doses are used
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

ICS

Warnings

A
  • High doses- use in caution in COPD patients with a history of pneumonia
  • Children- growth suppression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Antimuscarinic bronchodilators

Common indications

A
  • Asthma
  • COPD
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Antimuscarinic bronchodilators

MOA

A
  • Antimuscarinic drugs bind to the muscarinic receptors, where they act as a competitive inhibitor of acetylcholine
  • Stimulation of the muscarinic receptors brings about a wide range of parasympathetic rest and digest effects
  • In blocking the receptor, antimuscarinic have the opposite effect
    • Reduce smooth muscle tone
    • Reduce secretion from glands in the respiratory and GIT
    • Relaxation of pupillary constrictor, ciliary muscles preventing accommodation in the eye
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Antimuscarinic bronchodilators

Adverse effects

A
  • When antimuscarinic bronchodilators are taken by inhalation, there is relatively little systematic absorption
  • Adverse effects, apart from dry mouth are uncommon
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Antimuscarinic bronchodilators

Warnings

A
  • Antimuscarinics should be used with caution in patients susceptible to angle-closure glaucoma, in whom they can precipitate a dangerous rise in intraocular pressure
  • They should be used with caution in patients with or at risk of arrhythmias
  • However, in practice, most patients can take these drugs by inhalation without major problems
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Antimuscarinic bronchodilators

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Corticosteroids (Glucocorticoids) systemic

Common indications

A
  • Allergic or inflammatory disorders- anaphylaxis and asthma COPD
    • Only use in COPD on advise of a specialist
  • Suppression of autoimmune disease e.g. inflammatory bowel disease, inflammatory arthritis
  • In the treatment of some cancers as part of chemotherapy or to reduce tumour-associated swelling
  • Hormone replacement in adrenal insufficiency or hypopituitarism
17
Q

Corticosteroids (Glucocorticoids) systemic

MOA

A
  • These corticosteroid exert mainly glucocorticoid effects
  • They bind to cytosolic glucocorticoid receptors, which then translocate to the nucleus and bind to glucocorticoid-response elements, which regulate gene expression
  • Corticosteroids are most commonly prescribed to modify the immune response
  • They upregulate anti-inflammatory genes
  • Down regulate pro-inflammatory proteins
  • Direct actions on inflammatory cells include suppression of circulating monocytes and eosinophils
  • Their metabolic effects include increased gluconeogenesis from increased circulating amino and fatty acids, released by catabolism (breakdown) of muscle and fat
  • These drugs also have a mineralocorticoid effects, stimulating Na+ and water retention and K+ excretion in the renal tubles
18
Q

Corticosteroids (Glucocorticoids) systemic

Important adverse effects

A
  • Immunosuppression increases the risk and severity of the infection and alters the host response
  • Metabolic effects include diabetes mellitus (gluconeogenesis)and osteoporosis
  • Increased catabolism causes proximal muscle weakness, skin thinning with easy bruising and gastritis
  • Mood and behavioural changes- insomnia, confusion, psychosis and suicidal ideas
  • Hypertension, hypokalaemia, oedema can result from mineralocorticoid action
  • Corticosteroid treatment suppresses the pituitary adrenocorticotropic hormone (ACTH) secretion, switching off stimulus for normal adrenal cortisol production
    • In prolonged treatment, this causes adrenal atrophy- preventing endogenous cortisol secretion
    • If corticosteroids are abruptly withdrawn suddenly, an acute Addisonian crisis with cardiovascular collapse may occur
    • Withdraw slowly and allow recovery of adrenal function
    • Symptoms of chronic glucocorticoid deficiency that occur during treatment withdrawal include fatigue, weight loss and arthralgia
19
Q

Corticosteroids (Glucocorticoids) systemic

Warnings

A
  • Corticosteroids should be prescribed with caution in people with infection- worsening of infection
    • And in Children- growth suppression
20
Q

Corticosteroids (Glucocorticoids) systemic

Interactions

A
  • Corticosteroids increase the risk of peptic ulceration and GI bleeding when used with NSAIDs
  • Enhance hypokalaemia in patients taking B2-agonists, theophylline, loop or thiazide diuretics
  • Their efficacy may be reduced by CYP P450 inducers (Carbamazepine, phenytoin, rifampicin)
  • Corticosteroids reduce the immune response to Vaccines
21
Q

Corticosteroids (Glucocorticoids) systemic

Administration + Communication

A
  • OD corticosteroid treatment should be taken in the morning to mimic the natural circadian rhythm and reduce insomnia
  • State to patients that treatment should suppress the underlying disease process and that the patient will usually start to feel better within 1-2 days
  • For patients who require prolonged treatment, warn then NOT to stop treatment suddenly as this could make them very unwell
  • Give them a steroid card to carry with them at all times and show if they need treatment
  • Discuss longer-term risk: diabetes, osteoporosis + bone fractures
  • Patients on long term won’t be able to increase secretion in response to stress so should always carry steroids around with them
22
Q
A